Omega Therapeutics Temettü

Temettü kriter kontrolleri 0/6

Omega Therapeutics şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-0.05%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-0.05%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü güncellemeleri

Güncelleme yok

Recent updates

Omega Therapeutics GAAP EPS of -$0.54 in-line, revenue of $0.48M beats by $0.43M

Aug 04

Omega Therapeutics gets FDA nod to start liver cancer trial of lead drug OTX-2002

Jul 14

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: OMGA şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: OMGA şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Omega Therapeutics Piyasaya Karşı Temettü Getirisi

OMGA temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (OMGA)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.5%
Sektör Ortalaması (Biotechs)	2.2%
Analist tahmini (OMGA) (3 yıla kadar)	n/a

Önemli Temettü: OMGA şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, OMGA şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: OMGA şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: OMGA herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Omega Therapeutics Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

High number of new directors

Omega Therapeutics, Inc. Elects Robert L. Rosiello as Class I Director

Omega Therapeutics, Inc. Announces Publication of Epigenomic Controller OTX-2002 Preclinical Data in Nature Communications

Omega Therapeutics, Inc. Announces Executive Changes

Consensus revenue estimates increase by 30%

New major risk - Revenue and earnings growth

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Omega Therapeutics, Inc.(NasdaqGS:OMGA) dropped from Russell Small Cap Completeness Index

Omega Therapeutics, Inc. Appoints Richard N. Kender to Board of Directors

Omega Therapeutics, Inc. Appoints Kaan Certel, Ph.D., as Chief Business Officer

Consensus revenue estimates increase by 24%

Full year 2023 earnings released: US$1.80 loss per share (vs US$2.15 loss in FY 2022)

New major risk - Revenue and earnings growth

Omega Therapeutics, Inc., Annual General Meeting, Jun 20, 2024

Omega Therapeutics, Inc. Presents New Preclinical Data At AACR 2024 Supporting the Potential of Precision Epigenomic Control

Consensus revenue estimates increase by 43%

Price target decreased by 9.2% to US$11.20

Omega Therapeutics And Novo Nordisk Collaboration: A Cautious 'Buy'

Full year 2023 earnings released: US$1.80 loss per share (vs US$2.15 loss in FY 2022)

Is Omega Therapeutics (NASDAQ:OMGA) Weighed On By Its Debt Load?

Omega Therapeutics: The Next Weight Loss Drug Runner

Omega Therapeutics: Starting 2024 With A Bang

Consensus revenue estimates increase by 26%

Omega Therapeutics, Inc. Showcases Bidirectional and Multiplexed Epigenomic Control of Gene Expression in Preclinical Models of Liver Inflammation and Fibrosis

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Omega Therapeutics, Inc. Presents New Preclinical Data Supporting the Potential of OTX-2101 in Combination Settings for Treatment of NSCLC

New minor risk - Market cap size

Omega Therapeutics Announces Promising Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO I Trial

Price target increased by 8.6% to US$13.40

High number of new directors

Omega Therapeutics, Inc. Announces Board Changes

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Omega Therapeutics Appoints Chris Schade to Its Board of Directors

Price target decreased by 9.0% to US$11.83

Consensus EPS estimates upgraded to US$2.23 loss

Forecast to breakeven in 2025

Price target increased by 14% to US$14.80

Consensus revenue estimates increase by 57%

Board Member notifies of intention to sell stock

Forecast to breakeven in 2025

Price target decreased by 17% to US$13.00

Board Member notifies of intention to sell stock

Consensus revenue estimates increase by 62%

Price target increased to US$18.50

Omega Therapeutics Receives Orphan Drug Designation for OTX-2002 for the Treatment of Hepatocellular Carcinoma

Omega Therapeutics, Inc. Announces First Patient Dosed in Landmark MYCHELANGELO(TM) I Trial of OTX-2002 in Hepatocellular Carcinoma and Other Solid Tumor Types Associated with the MYC Oncogene

Omega Therapeutics, Inc. Unveils New Epigenomic Controller Development Candidate Targeting MYC Driven Non-Small Cell Lung Cancer

Omega Therapeutics, Inc. Announces Appointment of Rainer Boehm to its Board of Directors

Consensus forecasts updated

Price target increased to US$20.67

Omega Therapeutics GAAP EPS of -$0.54 in-line, revenue of $0.48M beats by $0.43M

High number of new directors

Omega Therapeutics, Inc. Announces U.S. Food and Drug Administration Clearance of IND Application for OTX-2002

Omega Therapeutics gets FDA nod to start liver cancer trial of lead drug OTX-2002

Omega Therapeutics, Inc. Presents New Preclinical Data Supporting the First Epigenomic Controller, Otx-2002, as A Potential Therapeutic Approach in Hepatocellular Carcinoma At the Esmo 2022 World Congress on Gastrointestinal Cancer

Omega Therapeutics, Inc.(NasdaqGS:OMGA) dropped from Russell 2500 Value Index

Omega Therapeutics, Inc. Announces Submission of Investigational New Drug Application for Otx-2002

Omega Therapeutics Announces Appoints Joshua Reed as Chief Financial Officer, Effective May 23, 2022

High number of new directors

Omega Therapeutics Inc. Announces Executive Changes

High number of new directors

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin